2014 Annual Report - The Wistar Institute

Transcription

WISTAR SCIENCE SAVES LIVES
ANNUAL REPORT 2014
A YEAR OF COLLABORATION
2014 was a remarkable year for The Wistar Institute. The $102 million building expansion project
was completed in September 2014 with the opening of the Robert and Penny Fox Tower. Beyond the
brick and mortar, the $35 million capital campaign Building Wistar, Changing the World is nearing
completion and will usher in vital new faculty and grow Wistar’s programmatic strengths in cancer
research, immunology and infectious disease.
Our scientists and staff exulted in the Fox Tower—a modern and exciting addition to Wistar’s campus
and the first new construction in 40 years. Meetings have come out from behind closed doors and
into the soaring piazza-like atrium. Scientists have made the open plan, light-filled laboratory spaces
thoroughly their home. 89,000 square feet and seven stories later, we are celebrating the moment—
and your support—that has allowed us to build for the future and do what we do best: Wistar Science.
2014 was also a series of pivotal moments. The remarkable work our scientists do at “the bench”
gained Wistar an “Exceptional” rating from the National Cancer Institute—the highest possible
rating a cancer center can earn. At the core of this effort was teamwork and collaboration. Last year
witnessed HIV expert Dr. Luis Montaner’s multi-institutional collaboration to begin the largest ever HIV
cure-focused clinical trial of its kind—based here in Philadelphia—to drain HIV reservoirs in affected
individuals; Dr. Meenhard Herlyn’s progressive melanoma work, bringing together the diverse expertise
of Wistar and Penn scientists, garnered a third Special Program of Research Excellence grant awarded
to the Institute; and Dr. Louise Showe’s research into lung cancer detection, now in clinical study with
industry partners, could make a simple blood test emerge as an important cancer diagnostic tool.
In these pages, we highlight Wistar’s advances in cancer research, strides to develop better vaccines,
and progress devoted to tackling HIV/AIDS, along with comprehensive accounts of our activities,
administration and governance. 2014 was undeniably seminal, but looking back or looking forward,
isn’t that true every year at Wistar?
DARIO C. ALTIERI, M.D. President & CEO of The Wistar Institute, Director of The Wistar Institute Cancer Center, and Robert and Penny Fox Distinguished Professor
RUSSEL E. KAUFMAN, M.D.
President Emeritus of
The Wistar Institute
2014 ANNUAL REPORT 3
THE FUTURE
IS NOW
We closed 2014 by announcing the evolution of Wistar leadership with Dr.
Dario C. Altieri succeeding Dr. Russel E. Kaufman as president & CEO in
March 2015. Dr. Kaufman’s 12 years at Wistar have brought unprecedented
scientific accomplishments and accolades, and his legacy has fortified the
Institute for years to come. Dr. Altieri is no stranger to Wistar. Since 2010,
he has been director of Wistar’s National Cancer Institute-designated Cancer
Center and Wistar’s first chief scientific officer. Dr. Altieri has galvanized
Wistar’s strength in cancer research, recruited world-class investigators and
charted a new path for translational medicine that accelerates the progression
from basic research to clinical trials with partners in industry and medicine.
CONTENTS
6 SCIENTISTS AND CLINICIANS IN
TANDEM CREATE BETTER MEDICINE
10 HIV CURE STRATEGY LEADS TO LARGEST
CLINICAL TRIAL OF ITS KIND
13 NEW TEST COULD CATCH LUNG CANCER
BEFORE IT BECOMES DEADLY
14 HERPES VIRUS REPLICATES BY
REARRANGING TELOMERES
16 COLLABORATION LEADS TO
PRESTIGIOUS NATIONAL GRANT
FOR MELANOMA RESEARCH
17 GRANT HONES IN ON CANCER GENETICS
AND CELLULAR SENESCENCE RESEARCH
18 BUILDING A BETTER FLU SHOT
21 REDEFINING THE BUSINESS OF
TRANSLATIONAL RESEARCH
22 BORN THIS WAY: THE WORK OF A
MILLENNIAL PHILANTHROPIST
This artistic rendering of a human
dendritic cell shows how membranes
fold back onto the surface of a cell
like a set of sheets. These sheetlike structures end up trapping
the HIV virus, and then eventually
the virus can be transferred to
helper T-cells, which contribute
to the infection. Photo credit:
National Cancer Institute (NCI)
24 DELIVERING ON A CAMPAIGN OF PROMISE
26 EVENTS
30 ANNUAL GIVING
34 HERITAGE SOCIETY
35 WISTAR FAMILY GIFTS
36 BOARD OF TRUSTEES
37 STAFF AND ADMINISTRATION
SCIENTISTS AND
CLINICIANS IN
TANDEM CREATE
BETTER MEDICINE
Dario C. Altieri, M.D., President & CEO of The Wistar
Institute, Director of The Wistar Institute Cancer Center,
and Robert and Penny Fox Distinguished Professor
In 2014, the National Cancer Institute (NCI) rated Wistar’s Cancer Center—
and its director, Dario C. Altieri, M.D.—as “Exceptional,” the highest possible
ranking, and recommended renewal of the Center’s Support Grant with a
$14.9 million award over the next five years.
Playing a significant role in securing renewed status as an NCI Cancer Center
was Wistar’s commitment to collaboration, both across disciplines and in
partnership with other institutions, including the Moulder Center for Drug
Discovery at Temple University, the Community College of Philadelphia, and
the Christiana Care Health System’s Helen F. Graham Cancer Center & Research
Institute in Delaware.
6 THE WISTAR INSTITUTE
In its Support Grant renewal, NCI described the Wistar-Graham Center partnership as “extraordinary
and innovative.” Wistar, the nation’s first NCI-designated cancer center solely devoted to cancer
biology research, and the Helen F. Graham Cancer Center, one of the first NCI-designated community
cancer centers, made history when they joined forces in 2011. It was the region’s first and only interinstitutional affiliation between a basic research institution and a community cancer center.
Access to quality patient-derived primary tumor samples from Christiana Care’s Tissue Procurement
Center enables Wistar scientists to better study a tumor’s microenvironment and determine how and
why cancer grows and spreads. Together, these two centers are working to more quickly “translate” or
advance discoveries in cancer medicine from the lab into early phase (Phase I and II) clinical trials with
cancer patients at Christiana Care. Given that 80 percent of oncology care is given at community cancer
centers like that at Christiana, the pairing is a natural fit. It also fosters opportunities for collaboration,
education and funding between researchers and clinicians that would not otherwise be feasible. The
end goal: better diagnostic and therapeutic interventions.
Some of the pioneering joint projects in basic biomedical science and translational cancer research
underway in 2014 include:
LUNG CANCER
Louise C. Showe, Ph.D., a professor in Wistar’s Molecular and Cellular Oncogenesis program and
director of the Institute’s Genomics Facility, together with Thomas Bauer, M.D., a thoracic surgeon at
the Helen F. Graham Cancer Center, are developing a blood test for detecting early stage non-small cell
lung cancer. Using blood samples contributed by lung patients through the Tissue Procurement Center,
Dr. Showe is working on a more sensitive, less invasive test that uses whole blood, which could easily
be drawn at the doctor’s office.
Above, this three-dimensional spheroid was grown from a line of melanoma cells that have a mutation of the NRAS gene. This
mutation, which helps the cancer grow and spread, occurs in up to 25 percent of melanoma patients and could be a useful
target for new therapies.
Scientists analyze tumor samples
to identify the genetic drivers of
various melanoma subtypes and try
to determine why some tumors are
resistant to treatment.
MELANOMA
Scientists in Wistar’s Melanoma Research Center, the nation’s largest melanoma laboratory outside of
the National Institutes of Health, are using tumor samples donated by patients undergoing melanoma
surgery at the Helen F. Graham Cancer Center. This invaluable resource provides director Meenhard
Herlyn, D.V.M., D.Sc., and his team with a vast range of melanoma subtypes, some previously
unavailable, with which they are working to identify genetic drivers and determine why some tumors
are resistant to treatment.
OVARIAN CANCER AND IMMUNITY
José Conejo-Garcia, M.D., Ph.D., professor and program leader for Tumor Microenvironment and
Metastasis at Wistar, has teamed up with gynecologic oncologists at Christiana Care on ovarian cancer
research. Dr. Conejo-Garcia uses tumor samples from the Tissue Procurement Center to verify that
previous animal model findings reflect what actually happens in human disease.
Dr. Conejo-Garcia wants to learn more about how ovarian cancer acts on the body’s natural defenses
to enable tumor growth. His laboratory is attempting to identify tumor surface markers that could
become targets for early detection—a critical need, considering there is currently no effective screening
test for ovarian cancer. His lab is also working to culture ovarian tumor cell lines to study tumor
progression and to test new drugs. Dr. Conejo-Garcia and his team co-authored two papers on this
work with gynecologic specialists at Christiana Care.
Christiana’s Tissue Procurement Center is also supplying custom-prepared, protocol-driven samples
of peripheral blood and cancer tumors to Dmitry Gabrilovich, M.D., Ph.D., and investigators in his
Translational Tumor Immunology program. They are looking at various types of myeloid cell defects
and how cancer impacts their role in the body’s immune response. Some of their proposed therapeutic
strategies to overcome these actions are being tested in clinical trials.
Above, this three-dimensional image of a melanoma cell was obtained using a special type of electron microscope that is able to
render cells that have a very small resolution. Photo credit: NCI
HIV CURE STRATEGY
LEADS TO LARGEST
CLINICAL TRIAL
OF ITS KIND
Luis J. Montaner, D.V.M., M.Sc., D. Phil.,
Herbert Kean, M.D., Family Professor;
Professor and Director, HIV-1 Immunopathogenesis Laboratory;
Member, Tumor Microenvironment and Metastasis Program
“With this funding, Philadelphia
will conduct the largest
randomized trial anywhere focused
on testing an easily accessible
strategy to advance an HIV cure.”
Dr. Luis J. Montaner
When patients with the human immunodeficiency virus (HIV) are treated successfully, a small amount
of the virus can linger in cells, ready to accumulate and multiply rapidly, thus making the disease
impossible to cure. Now, research that originated at The Wistar Institute aims to deplete the HIV
virus from these “viral reservoirs.” At a time when many HIV cure strategies are still being tested in
small pilot studies, Wistar will move forward with the first National Institutes of Health (NIH)-funded
randomized trial on a strategy directed at a cure.
Luis J. Montaner, D.V.M., D.Phil., received a four-year, $6.2 million grant from the National Institute of
Allergy and Infectious Disease of the NIH to test this new strategy. Dr. Montaner conducted a pilot trial
showing that interferon-alpha, a protein that modulates the immune system, can reduce the persistent
amount of HIV-1 residing in people with HIV/AIDS who currently receive treatment with antiretroviral
therapy.
Current therapies keep the virus at bay, but never reduce the amount of the virus that remains in the
patient.
“An HIV cure will require going beyond current therapies, and our strategy has shown itself capable of
doing that,” said Dr. Montaner. “With this funding, Philadelphia will conduct the largest randomized
trial anywhere focused on testing an easily accessible strategy to advance an HIV cure.”
Dr. Montaner is collaborating with multiple clinics across Philadelphia under the supervision of
Jay R. Kostman, M.D., a clinical professor of medicine in the Division of Infectious Diseases at the
Perelman School of Medicine at the University of Pennsylvania. They will supervise a randomized trial
of 54 patients to conclusively determine the effectiveness of this strategy. The team is comprised of
investigators and clinicians based at The Wistar Institute, the University of Pennsylvania, the University
of California, and Philadelphia FIGHT.
The $6.2 million grant will go toward clinical and administrative expenses of the trial as well as the
laboratory follow-up allowing researchers to quantify their results. Laboratory results look to determine
how quickly HIV-1 replicates following interruption of antiretroviral therapy, the amount of HIV DNA
integrated into host T cells, and the amount of virus hiding in reservoirs. Dr. Montaner’s lab will also
examine the mechanics of how the immune system responds to the immunotherapy.
Above, HIV attacks and destroys the infection-fighting T-cells, which are crucial to the immune system’s ability to fight off
invading viruses and germs. Once in the body, the virus can replicate over and over again until the infected cells outnumber the
healthy T-cells. Photo credit: National Institute of Allergy and Infectious Diseases (NIAID)
Louise C. Showe, Ph.D., Professor,
Molecular and Cellular Oncogenesis
Program; Associate Director, Center
for Systems and Computational
Biology; Scientific Director,
Genomics Facility; and Scientific
Director, Bioinformatics Facility
NEW TEST COULD CATCH
LUNG CANCER BEFORE IT
BECOMES DEADLY
A new, easy-to-use blood test developed at The Wistar Institute could detect lung cancer before it
spreads. A clinical trial to gauge the test’s effectiveness is underway, and its organizers report it has
reached its goal of 600 volunteer participants who are considered at high-risk for developing lung
cancer.
This tool was developed at Wistar by Louise Showe, Ph.D. In a series of previous studies, Dr. Showe
demonstrated that lung cancer could be detected before symptoms appear by taking a snapshot of
gene activity in blood-borne immune cells.
The need for early detection is important in all types of cancer, but this is especially true in lung
cancer. The rate of survival for patients with lung cancer drops dramatically the later it is detected.
Patients diagnosed with non-small cell lung cancer at stage IA, or very early stage lung cancer, have
a 49 percent chance of survival five years after diagnosis, according to the American Cancer Society.
However, patients who are diagnosed with stage IV disease, which means the cancer has metastasized
and spread to other organs, have only a 1 percent chance of achieving five-year survival.
By October 2014, more than 600 blood samples from patients considered at high-risk for developing
lung cancer had been collected at six clinical sites, including the Helen F. Graham Cancer Center in
Delaware and Temple University Hospital in Philadelphia. All sites met or exceeded their collection
goals. Wistar scientists are currently looking at this data and analyzing gene expression signatures, or
the molecular “fingerprints” that disclose the presence of lung cancer.
“The need for more sensitive, cost-effective, and less invasive
methods to detect and monitor cancer in humans, particularly
in lung cancer, is not going away,” said Dr. Showe. “We look
forward to expanding our studies through this collaboration
in order to detect and monitor this devastating cancer.”
Lung cancer lesion
There are two main types of lung cancer. Most are non-small-cell lung cancer,
shown here at right. Small-cell lung cancer is more aggressive and likely to
spread to other parts of the body early on. Photo credit: James Heilman, M.D.
HERPES VIRUS
REPLICATES BY
REARRANGING
TELOMERES
Paul M. Lieberman, Ph.D., Hilary Koprowski, M.D.,
Endowed Professor; Professor and Program Leader, Gene
Expression and Regulation Program; Director, Center for
Chemical Biology and Translational Medicine; and Scientific
Director, Protein Expression and Libraries Facility
The herpes simplex virus 1 (HSV-1), shown in green, is able to rearrange telomeres,
the small protective ends of DNA that protect our chromosomes, shown in red. This
viral-manipulation might explain why the herpes virus is able to replicate so effectively
in older cells where telomeres are shorter due to aging.
Herpes simplex virus 1 (HSV-1) is the aggressive virus closely associated with cold sores, which can lead
to more severe disease. The virus can rearrange the crucial protective ends of our chromosomes called
telomeres. These findings show how a virus like herpes is able to multiply while also revealing more
about the role of telomeres, which prevent our chromosomes from breaking, and their ability to stop
viruses in their tracks.
The results were published by the journal Cell Reports.
Paul Lieberman, Ph.D., lead author of this study, said that telomeres play a very important part in the
lifespan of a cell.
“We wanted to know whether they also play a role in viral replication or protection from viruses, and
our findings suggest—at least in the case of the herpes simplex virus—that this may indeed be the
case,” Dr. Lieberman said.
Telomeres keep chromosomes from unwinding and breaking (much like the clear tips on the end
of shoelaces that prevent fraying). This is crucial because chromosomes hold all of our vital genetic
information.
This lab studied HSV-1 because it’s an aggressive virus able to replicate in the cell nucleus where our
chromosomes and telomeres are found. Commonly known for causing cold sores, HSV-1 can also lead
to more serious diseases like blindness and encephalitis. About 65 percent of Americans show signs of
past infection; and there is no vaccine for the virus and only a small handful of effective treatments.
The study by Dr. Lieberman and his colleagues found that the virus can degrade a telomere protein
called TPP1, which is part of a complex of proteins furnishing protection to telomeres. When the TPP1
protein is shut down, HSV-1 uses a protein called ICP8 to promote viral genomic replication.
“This study expands our knowledge of telomeres further in two very important ways,” Dr. Lieberman
said. “First, it gives us an indication that some viruses are able to manipulate telomeres specifically in
order to replicate. Second, it appears that proteins like TPP1 provide very specific protective functions.
These findings allow us to ask additional questions and better understand just how telomeres may
protect cells from viral infection.”
Dr. Lieberman’s research could eventually bridge the gap to clinical application.
“Paul’s work is not only groundbreaking but tremendously promising,” said Dr. Russel E. Kaufman,
president emeritus of The Wistar Institute. “Fundamental research efforts lead to discoveries and are
always where we have the greatest potential for life-saving treatments.”
COLLABORATION LEADS TO
PRESTIGIOUS NATIONAL GRANT
FOR MELANOMA RESEARCH
In September 2014, Wistar announced the receipt
of a $12.1 million Special Program of Research
Excellence (SPORE) grant to develop new therapies
for melanoma—the deadliest form of skin cancer
and the fifth deadliest form of cancer, overall. This
prestigious National Cancer Institute collaborative
grant brings together researchers at Wistar and the
University of Pennsylvania to translate fundamental
laboratory discoveries into new therapeutics that
will benefit patients with melanoma and other
skin cancers. Wistar is the first basic research, NCIdesignated Cancer Center to be awarded a SPORE
grant.
Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar
Professor in Melanoma Research and Director, The
Wistar Institute Melanoma Research Center
Melanoma cells are grown as
three-dimensional spheroids
embedded in collagen to mimic
the tumor microenvironment
(cells, molecules and blood
vessels that surround and feed
a tumor) and can then be
studied. The green fluorescence
indicates live cells and the red
fluorescence indicates dead cells.
Meenhard Herlyn, D.V.M., D.Sc., principal
investigator on the grant, will lead this collaborative
effort with cutting-edge research on new
melanoma therapies, strategies and diagnostics—
the result of over 30 years of teamwork that has
evolved between Wistar and the University of
Pennsylvania. Further, the SPORE grant will be
a model to establish an organizational structure
on campus for future research on melanoma and
other skin cancers.
Specifically, the grant will fund four melanoma
research projects that explore new therapies and
cancer genetics: targeted combination therapy,
autophagy modulation, genetic marker research
related to certain therapies, and engineered T cell
therapy. It also supports three “cores” of work to
further support the team’s efforts: an administrative
core to support collaboration between researchers,
a biospecimen and pathology core to provide
researchers with high-quality tumor samples, and
a biostatistics core to help analyze and disseminate
research on experiments and clinical studies.
GRANT HONES IN ON CANCER
GENETICS AND CELLULAR
SENESCENCE RESEARCH
Building on a deeply-rooted commitment to
advance our understanding of cancer genetics,
Wistar was awarded a $100,000 grant from The
W.W. Smith Charitable Trust in December 2014
for research on cellular senescence—a state of
stable cell growth arrest—that suppresses the
development of human cancers. The W.W. Smith
Charitable Trust is a private foundation that
provides funding to support basic medical research
primarily in the areas of heart disease, cancer and
AIDS.
Led by Ken-ichi Noma, Ph.D., the project—titled
“Regulation of Cellular Senescence Through 3-D
Genome Organization”—will investigate how
alterations in the 3-D genome architecture affect
gene expression and drive cellular senescence.
Throughout his career, Dr. Noma has been hard
at work to better understand the molecular
underpinnings of human cancers, especially
cancers that result from the disorganization of
the cell nucleus. He uses a variety of investigative
mechanisms to regulate the genome structure and
better understand its biological significance. At a
time when cancer is on the rise, the grant will allow
for a more focused look, using the latest technical
advances, into cellular senescence and complex
3-D genome structures.
Ken-ichi Noma, Ph.D., Associate Professor, Gene
Expression and Regulation Program
As we age, our cells eventually
become senescent, meaning
that they lose their ability to
grow and divide. Dr. Noma has
discovered that the chromosomes found in these senescent
cells are organized differently
than in normal, healthy cells.
If we could turn cancer cells into
senescent cells, they would stop
growing, and this might help
slow down the progression of
the tumor. Knowing this could
allow researchers to either
reverse senescence in healthy
cells or increase senescence in
cancerous cells.
Jan Erikson, Ph.D.,
Professor, Vaccine Center
BUILDING
A BETTER
FLU SHOT
Every fall, Americans dutifully get flu shots and
anticipate the vaccination will protect them
against that season’s virus strain (or strains). Some
years the vaccines are better than others, but the
risk of serious illness from influenza remains a
threat—the seasonal influenza virus kills 36,000
Americans annually and is the nation’s eighth
leading cause of death. Two investigators in
Wistar’s Vaccine Center are studying the biology
of influenza infection to make annual flu shots
more effective, as well as investigating ways at
reducing secondary infection. Both scientists
published papers in 2014 on recent flu-related
discoveries.
If a secondary respiratory infection like bacterial
pneumonia (pneumococcus) develops following
a bout with the flu, there’s a greater risk of
becoming sicker or even dying. Professor Jan
Erikson, Ph.D., discovered that if the order of
infection is reversed—if the flu infects after
Scott E. Hensley, Ph.D.,
Assistant Professor, Vaccine Center
pneumococcus is already present—it may be possible to actually protect patients against severe flurelated illness. Her research was recently published in the journal Virology.
Scientists in Dr. Erikson’s lab demonstrated that if the respiratory tract of mice is colonized with
pneumococcus prior to exposure to influenza, the virus is significantly less likely to be severe or progress
to a secondary infection. This discovery can help researchers advance potential strategies to prevent
secondary bacterial infections and improve overall outcomes.
Another Wistar study examined why during the 2013-2014 flu season middle-aged adults got sicker
than typically more vulnerable populations of children and the elderly. Led by Scott E. Hensley, Ph.D.,
the team of investigators identified a mutation in recent H1N1 influenza strains allowing viruses to
avoid immune responses present in nearly half of adults born between 1964 and 1979, leading to
increased disease incidence.
His team’s data suggests that previous influenza exposure in the 1970s and 1980s influenced how
middle-aged people responded to the current H1N1 vaccine. Published in Proceedings of the National
Academy of Sciences, the findings suggest the need to update the seasonal flu vaccine each year with
new viral strains to help build broader immunity.
Both Drs. Erikson’s and Hensley’s discoveries inform the Vaccine Center’s ongoing work in pursuit of a
single, universal seasonal influenza vaccine to ultimately replace yearly injections, and the uncertainty
that accompanies them.
The Business Development team consists
of (clockwise from left) Heather A.
Steinman, Ph.D., M.B.A., Vice President
for Business Development and Executive
Director of Technology Transfer,
Christopher Harold Croft, Contracts and
Intellectual Property Specialist, Kathy
Day, Administrative Coordinator, and
Dustin Shilling, Ph.D., Senior Associate of
Licensing and Business Development.
REDEFINING THE BUSINESS
OF TRANSLATIONAL
RESEARCH
The Wistar Institute is known for its nimble approach to research and support for unfettered
innovation. So too, is Heather A. Steinman, Ph.D., M.B.A., Wistar’s dynamic new vice president for
Business Development and executive director of Technology Transfer. Steinman is revitalizing Wistar’s
technology commercialization activities, tearing down silos and removing any barriers that might stand
in the way of the transformative, life-saving possibilities of Wistar Science.
Steinman’s creative vision is to unite scientists with strategic partners in the life sciences start-up
community and pharmaceutical industry with the goal of converting Wistar’s growing repertoire
of targeted cancer treatments, diagnostics, vaccines, and discovery platforms into biomedical
breakthroughs. This catalytic approach to removing the risks from early stage science ensures a higher
likelihood for success and accelerates the opportunity for innovative projects to move forward.
To help translate Wistar’s special brand of biomedical research into life-saving solutions, while also
generating income to support further research and education, Steinman relies on her team of experts:
Dustin Shilling, Ph.D., senior associate for licensing and business development, Christopher Harold
Croft, contracts and intellectual property specialist, and Kathy Day, administrative coordinator.
“We can do business in a proactive, accelerated way at Wistar—we have no red tape, which enables
us to harness our efforts toward the end goal, not the bureaucratic process,” said Steinman. “Wistar’s
stellar science is a powerful portfolio for pre-clinical target discoveries. What an exciting time to be part
of Wistar and to have this agile dynamic team that can step in early to leverage our assets and nurture
valuable industry relationships for our researchers and the Institute.”
For Steinman, the key to success is about the connections. In business, it has to be personal.
At center stands Lynsie Solomon,
Wistar Ambassador Founder
and Chair, surrounded by Wistar
Ambassadors at the Sips, Schmooze
& Science event at the Capital Grille.
BORN THIS WAY:
THE WORK OF A MILLENNIAL PHILANTHROPIST
Wistar Institute Leadership Council member and Wistar Ambassador founder and chair Lynsie Solomon
has arrived early for the Sips, Schmooze & Science event, and steps into Wistar’s new atrium with a
close-knit ring of supporters including her mom, friends and Wistar Ambassadors. Each one carries a
bag brimming with raffle items: spa day lotions and potions, ties and scarves, bottles of top shelf liquor,
and gift certificates as well as the necessities for gift wrapping: cellophane, wicker baskets, ribbon,
and scissors. Two hours later, seven high-end raffle baskets combined with ticket sales raise more than
$4,000. It’s just another day after her day at the office; a night of do-gooding, cementing ties and
making an impact.
Lynsie is committed to being part of something greater than herself. Though she has a full-time job,
she finds time to be a young member of numerous esteemed arts and science organizations, including
a committee member and 2016 vice chair of the Young Friends of the Academy of Music, 2015 cochair of the Ladies Committee of the Union League, a member of the Sidney Kimmel Cancer Center
Next Generation, and a sponsorship chair board member for Donors Are Heroes.
“When I was growing up, my parents were very involved in charitable work and they taught me to
give—both money and time,” Lynsie said. “My husband Evan’s mentors have exposed us to events
with a cause and, through like-minded people, we have learned about the many social issues and
needs in Philadelphia.”
Happening upon a Wistar event through a friend, Lynsie wanted to get to know Wistar at a deeper
level, and returned to meet and tour the Wistar campus with Dr. Russel E. Kaufman, president emeritus.
“I was empowered when I met Dr. Kaufman—how can anyone not get involved with Wistar when
they meet him?” said Lynsie. “I learned what a scientific powerhouse Wistar is in cancer research and
vaccine work, and concluded that Wistar scientists should never have to fear interrupting or stopping
their research. I simply asked how could I help.”
The mantra “Wistar Science Saves Lives” was a clear, strong mission statement that attracted Lynsie
to the Institute.
“I want to be a part of an organization making huge strides—and, basically, saving the world,” Lynsie
explained. “Wistar is doing that on all levels. The scientists working ‘at the bench’ are the best of the
best in understanding the basic mechanisms behind melanoma, breast, ovarian, and prostate cancers.
And now there’s so much progress in translating their discoveries to therapies. Wistar’s mission makes
my head spin with excitement.”
Lynsie and her husband, Evan Solomon, came aboard as Wistar Leadership Council members in 2013.
At meetings, they quickly realized that they were the youngest people in the group.
“I had a great mentor in (former Leadership Council chair) Ed Ryan and he motivated me to get more
involved,” Lynsie explained. “I felt like it was a great opportunity to engage young people in Wistar’s
work. Then I worked with Elyse Hoffmann, Wistar donor relations and special events director, on our
first event and that forged a strong relationship.”
Lynsie and Elyse combine their skill sets and expertise to create events that are cementing relationships
with ambitious, new philanthropists in and around Philadelphia. These next generation supporters
bring a fresh perspective to Wistar and are committed to investing their time, money and energy.
“I would like to see twice as many Ambassadors and be able to raise a substantial donation to give in
2015,” Lynsie stated. “The Ambassadors aren’t here to enjoy just another happy hour. They are here
for the long haul and are engaged and passionate about the work Wistar does.”
Ambassador founder and chair
Lynsie Solomon and Evan Solomon
COCKTAILS AND
BITES WITH
THE WISTAR
AMBASSADORS
Ambassador member
Gabriela Guaracao and
Matthew Fontana
Andrew Peshek and Ambassador
member Leah Reinhard
MARCH 19, 2014, AT ROSA BLANCA IN PHILADELPHIA
The Wistar Ambassadors are a group of young residents in the Philadelphia
region 40 years old and under who want to learn more about Wistar’s bold
new advances in cancer research and find new ways of raising local and
national awareness of these efforts.
At this inaugural party, guests spent the evening in an exclusive and intimate
setting as Russel E. Kaufman, M.D., president emeritus of The Wistar Institute,
was on hand to discuss the important science taking place at Wistar and
answer questions from this young group of Philadelphians.
All photos courtesy of HughE Dillon.
DELIVERING ON
A CAMPAIGN
OF PROMISE
In 2010, Wistar announced a five-year, $35
million capital campaign—Building Wistar,
Changing the World—designed to sow
the seeds for its first major building project
since 1976 and secure the Institute’s future
at the forefront of cancer research, genetics
and vaccine development. The opening of
the much-anticipated Robert and Penny Fox
Tower in September 2014 heralded a new
era of team science at Wistar, with enhanced
cross-disciplinary collaboration and new
partners in medicine and industry that will
accelerate basic biomedical discoveries into
life-saving inventions.
Erecting the cutting-edge $100 million
research facility and equipping scientists
with the latest technologies were only part
of the first phase of the campaign’s objective.
Funds raised will complete remaining aspects
of the expansion and support a $10 million
initiative to recruit world-class scientists who
will complement the strengths of Wistar’s
faculty while broadening capabilities in
pioneering new areas of research.
Thanks to the leadership of Robert and
Penny Fox and the generous support of
the board of trustees, the capital campaign
steering committee, and numerous
individuals, the campaign has raised more
than $30.5 million—an investment in
Wistar’s paramount mission to save lives as
it heads into the final year of the campaign.
“Caspar” hangs at the main entrance of the Robert
and Penny Fox Tower and is named after Caspar
Wistar, M.D. Symbolic of a DNA helix, its smooth
center curve anchors protein tendrils and Wisteria—
named by the botanist Thomas Nuttall after his friend
Dr. Wistar. Made of painted brass mesh and copper,
the kinetic sculpture makes a full rotation every six
minutes and was created by visual artists Kate Kaman
and Joel Erland.
At the top of the Fox Tower’s grand stairway is the Atrium, the
principal point for circulation between the historic and new
buildings. This light-filled, inspiring gathering space welcomes
visitors and students alongside scientists and distinguished
guests to an open and inviting plaza that enhances Wistar’s
mission of discovery, collaboration and community.
The stunning visual focus of the Atrium is the Feature Wall, a
series of 15 high-definition TV screens that presents dynamic
images and visual programming to highlight the Institute’s
science, scientists and stories as well as educate and inspire an
appreciation of science and its immense impact.
EVENTS
THE WISTAR INSTITUTE’S
MELANOMA AWARENESS DAY
WITH THE PHILLIES
Presented by Citizens Bank
and Independence Blue Cross
Wistar’s Melanoma Awareness Day at Citizens
Bank Park was stellar. Dr. Russel E. Kaufman,
president emeritus, threw out the ceremonial
first pitch in front of a crowd of more than
30,000 baseball fans, and the busy night proved
ideal for Wistar to spread the message of
melanoma prevention. Also, through the Phillies
Charities, Inc., 50/50 Drawing, Wistar received
$5,378.75—a quarter of the proceeds from the
drawing’s raffle sales collected on game night.
1
2
5.13.2014
3
4
6
7
1. Daniel K. Fitzpatrick, Citizens Bank President and CEO of PA/NJ/
DE/NY; and Russel E. Kaufman, M.D., Wistar president emeritus
2. Russel E. Kaufman, M.D., throws out the first pitch
3. Wistar scientists and the Phillies Phanatic take a bow after
dancing on the dugout
4. On the Jumbotron, Phillies Hall-of-Famer and stage-3 melanoma
survivor Mike Schmidt spread the message of sun safety to a
packed ballpark
5. Three young baseball fans show “they all have skin in this game”
with Wistar wrist bands and sunglasses
6. Wistar volunteer and graduate student Amanpreet Kaur hands
out sunblock and sun-sensitive wrist bands to the crowds at the
ballpark entrance
5
7. Wistar friends and scientists enjoy a night out at the ball park
EVENTS
19TH ANNUAL ALBERT R.
TAXIN GOLF & BRIDGE CLASSIC
A vivid green golf course seemingly endless
under breezy, clear blue skies contributed
to an outstanding day of golf and bridge
at the Green Valley Country Club in
Lafayette Hill, Pa. The Albert R. Taxin Golf
& Bridge Classic, established to honor the
memory and legacy of Albert R. Taxin,
raised record-setting proceeds to support
the vital work taking place in the Albert R.
Taxin Brain Tumor Research Center at The
Wistar Institute.
5.19.2014
1
2
3
1. A perfect sunny day was par for the course for Robert A. Fox and Coach Dick Vermeil.
5
2. Event co-chair Garry Maddox and John Binswanger pause for a photo during the reception
3. Robert A. Fox, Alan Miller, and president emeritus Dr. Russel E. Kaufman
4. Wistar volunteers handling the check-in table: Kate O’Neill, Tina Ciarrocchi, Alan
Spooner, Rita Manfre, Mary Fenkel and Claire Rose
5. Foursome golfers Peter Brandow, Karen Schulze, Laura and Mark Lenet
6. Team golfers Bruce Downs, Sandy and Louis Rousso and Anthony Dent
7. Marybeth Driscoll, Ralph Wellington, and Mary Bak took a break from some memorable
shots on par
6
4
7
EVENTS
PRESIDENT’S AWARD
LUNCHEON HONORING
ALLAN H. (BUD) SELIG
Allan (Bud) Selig, the commissioner emeritus
of Major League Baseball, was the 2014
recipient of The Wistar President’s Award.
The President’s Award recognizes a public
figure who has been personally touched by
cancer, and who advocates for improvements
in cancer education and research. Selig is an
outspoken melanoma cancer survivor who
uses the ballpark as his platform to raise
awareness about melanoma, the deadliest
form of skin cancer.
5.28.2014
2
3
4
1. Dr. Jerry Herman, Bud Selig, Abe
Morris, and Dr. Russel E. Kaufman,
president emeritus
2. Wistar’s, melanoma team with the
MLB Comissioner: Drs. Meenhard
Herlyn, Ashi Weeraratna, Maureen
Murphy, and Jessie Villanueva
3. Bud Selig and Joe Grusemeyer
4. Wistar Board Trustee Chair Helen
Pudlin, Bud Selig, and Board member
Ronald Caplan
5. Sandra and Michael Widlitz, Kate
O’Neill, director and president of
the Noreen O’Neill Foundation
for Melanoma Research, and
Dr. Meenhard Herlyn, Director of
Wistar’s Melanoma Research Center
6. Guests at the President’s Award
Luncheon in the Diamond Club at
Citizens Bank Park
6
1
5
EVENTS
UNVEILING OUR NEW
TOWER: THE ROBERT &
PENNY FOX TOWER GALA
There could not have been a more
distinctive and appropriate celebration
of the Robert and Penny Fox Tower than
the red carpet affair that took place on
September 12, 2014. Wistar’s highlyanticipated gala kicked off with a ribboncutting ceremony by president emeritus
Dr. Russel E. Kaufman—with General Isaac
J. Wistar’s ceremonial Civil War sword in
hand—officially slicing the ribbon and
signaling the start of a brilliant evening of
entertainment. Guests were led up to the
5th and 6th floor laboratories, where they
sipped cocktails out of test tubes and talked
about the future of Wistar science. They
enjoyed a magnificent dinner, served by lab
coat-clad servers, on the main floor of the
new research tower. BalletX performed, an
oxygen bar offered aromatherapy scents
and conversations continued into the night.
1
2
3
9.12.2014
4
5
1. Robert and Penny Fox are presented with a
model of the Tower
2. Wistar Leadership Council member James Li
with wife Audrey
6
3. State Senator Anthony Williams, Robert A. Fox,
Dr. Russel E. Kaufman, Penny Fox, and State
Rep. James Roebuck gather for the ceremony
4. Abe Morris, Art Pappas, Dr. Jerry Herman, and
Dr. Dario C. Altieri enjoy cocktails in a lab of
the Fox Tower
5. Rick Horowitz, Joseph Kestenbaum, Ruth
Horowitz, Max and Elyse Berger, and Sharon
Kestenbaum together in the new atrium of the
Fox Tower
6. Wistar’s glamorous scientists
7. BalletX ballerinas surprised guests with a
“pop up” performance during dinner
8. A view of the Atrium from above
7
8
ANNUAL GIVING
THANK YOU
The Wistar Institute wishes to thank all of our donors who generously invest in our mission to contribute to the
prevention and cure of cancer and related diseases. Each of these individuals, corporations, and foundations listed
below made a gift of $500 or more between January 1 and December 31, 2014.
ISAAC WISTAR SOCIETY $500,000+
Anonymous
Innisfree Foundation
Wellcome Trust
W. W. Smith Charitable Trust
CENTENNIAL SOCIETY $100,000+
Ira Brind and Stacey Spector
The Horace W. Goldsmith Foundation
The G. Harold & Leila Y. Mathers Charitable Foundation
Melanoma Research Alliance
PTS Foundation
Dr. Karl F. Rugart, Jr.*
Sibley Memorial Hospital
Mrs. Frances Tobin
PATRONS $50,000+
Alliance for Cancer Gene Therapy
American Cancer Society
Nancy and Robert S. Blank
Ellen and Ronald Caplan
Connelly Foundation
The Doctors Cancer Foundation
Jane and Joseph Goldblum
Herbert Kean, M.D. and The Honorable Joyce Kean
Mr.* and Mrs. Thomas F. Lafferty
Mr.* and Mrs. Herbert Lotman
Martha and I. Wistar Morris III
Noreen O’Neill Foundation for Melanoma Research
The Philadelphia Foundation
Seymour S. Preston III and Jean E.H. Preston
Mr. and Mrs. Gerald B. Rorer
GUARANTORS
$10,000+
Robert and Marta Adelson
Mary Rhoads Alexander
Mr. David Anderson and Mrs. Elizabeth McKee Anderson
Ballinger Architecture & Engineering
Mrs. Ian J. Berg
Mr. and Mrs. Max M. Berger
BNY Mellon Wealth Management
Mr. and Mrs. Douglas S. Briggs
Mrs. June H. Chern
Citizens Bank
Mr. and Mrs. Harold M. Davis
John and Rosemary Diederich
Brian and Elizabeth Dovey
Mr. and Mrs. Joseph J. Fenkel
Ms. Debra Fox
Mr. Kenneth A. Fox
Ms. Nancy Fox and Mr. Jon Edwards
Dr. L. Patrick Gage and Ms. Irina Wilson-Gage
Stan & Arlene Ginsburg Family Foundation
The Anne M. and Philip H. Glatfelter, III Family Foundation
Mr. and Mrs. Bruce A. Goodman
Reuben and Mollie Gordon Foundation
Mr. and Mrs. Donald C. Graham
Gray Charitable Trust
Marcy Gringlas and Joel Greenberg
The Hassel Foundation
Hess Foundation, Inc.
Ruth and Richard Horowitz
Independence Blue Cross
Janssen Biotech Services, Inc.
W. M. Keck Foundation
Mr. Martin P. Krasner
Mr. Perry Lerner and Ms. Lenore Steiner
LF Driscoll
Mr. Ira M. Lubert
Susan and Graham McDonald
Mr. and Mrs. Alan B. Miller
Morphotek, Inc.
Mr. and Mrs. Abraham L. Morris
The Warren V. Musser Foundation
Albert Ominsky, Esquire and Paula Dresnin
Pennsylvania Breast Cancer Coalition
Philadelphia Phillies
PNC
Helen and David Pudlin
RAF Industries
Mr. and Mrs. Robert H. Rock
Martha W. Rogers Charitable Trust
Mr. and Mrs. Lester Rosenfeld
Mr. and Mrs. Ronald Rubin
Mr. Seymore Rubin
Paul and Sharon Schmitt
Schnader Harrison Segal & Lewis LLP
William A. Slaughter, Esquire
Doris Taxin and Jack Stievelman
Mr. James D. Troyer and Ms. Kathleen Callan
Mr. and Mrs. Richard A. Vermeil
Mr. and Mrs. David V. Wachs
Samuel Waxman Cancer Research Foundation
Mr. and Mrs. Bryan S. Weingarten
Dan Wheeler and Amy Fox
PRESIDENT’S SOCIETY INSURERS $5,000+
Mr. and Mrs. William A. Albert
American Heart Association
The Arthur Jackson Company
The Barra Foundation
Mr. and Mrs. John K. Binswanger
Ms. Stacy Chern and Mr. Ty Wu
Ellen and Winston Churchill
Colonial Consulting, LLC
Sandy and Stephen Cozen
Mrs. Margaret F. Cristofalo
Drexel University
Eli Lilly and Company
Mr. and Mrs. Mark Fishman
Penny and Robert Fox
Mr. and Mrs. Steven C. Graham
Dr. and Mrs. Peter Gross
Estate of Arthur Hermann
The Honickman Family
Dr. and Mrs. Russel E. Kaufman
Mr. and Mrs. Joseph Kestenbaum
Mr. and Mrs. H. Lewis Klein
Dr. Christopher Koprowski
Jane and Leonard Korman
Susanna Lachs and Dean Adler
Garry Maddox, A. Pomerantz & Co.
Henry S. Miller, Jr. and J. Kenneth Nimblett
Maida R. Milone
Mr. David P. Montgomery
Oxford Area Foundation
Mr. and Mrs. Arthur Pappas
Dr. and Mrs. Stanley A. Plotkin
The Edward and Elsa Rhoads Trust
William and Inés Rhoads
Mr. Brett Rhode
The Scholler Foundation
Judith Soltz and Richard Belas
Susan R. and John W. Sullivan Foundation
Mr. C. Cresson Wistar
PRESIDENT’S SOCIETY DIRECTORS $2,500+
Mr. Robert Angevine
Ms. Mary E. Bak
Cozen O’Connor
Kenneth J. Davis, Esq. and Susan Charleston
Dolfinger-McMahon Foundation
Father’s Day Mother’s Day Council, Inc.
Firstrust Bank
Mr. and Mrs. Bruce A. Gillespie
Helen F. Graham Cancer Center at Christiana Care
Mr. Joseph F. Grusemeyer
Mr. and Mrs. Laurence Holbert
Mr. and Mrs. Ira M. Ingerman
Mr. Leroy E. Kean
Mr. and Mrs. Tom Kirchhoff
Ms. Agatha Koprowski
Mr. and Mrs. Seymour G. Mandell
Jennifer Mendel and Fred Fox
E. K. Pomerantz Miller
National Catholic Community Foundation
NAXION
Mr. and Mrs. Timothy Pesce
E. Prem Reddy, Ph.D.
Anne Rhoads and Noureddine Melikechi
Mr. and Mrs. Ernest Scheller, Jr.
Mr. and Mrs. Fred Shabel
Elaine Shapiro
Ed Sickles Family
Lynsie and Evan Solomon
Greg and Alex Stanbach
Universal Health Services, Inc.
University of Colorado School of Medicine
Veritable, LP
Mr. and Mrs. Laurence N. Weiss
Willis of Pennsylvania, Inc.
PRESIDENT’S SOCIETY FELLOWS $1,000+
Mr. Michael Ackerman
Mr. and Mrs. Benjamin Alexander
Mr. Scott Barsky
Joseph Boardman, Esq.
Dani P. Bolognesi, Ph.D.
Mr. and Mrs. Martin Brait
Mrs. Barbara Cantor
Dr. Catherine Chern and Mr. John Auyeung
David and Rhonda Cohen
Mr. and Mrs. Matt Cohen
Mr. and Mrs. Norman Cohn
Comcast-Spectacor
Debbie and I. Michael Coslov
Carlo M. Croce, M.D.
Joanne and Donnie Davidow
Joan M. Farkas and Bruce T. Downs
Mr. and Mrs. Joseph M. Field
First Federal of Bucks County
Fisher Scientific
Mrs. Annabelle Fishman
Mr. and Mrs. Richard J. Fox
Mrs. Linda Frankel
Mr. and Mrs. P. Richard Frieder
Mrs. Honey Friedman
William and Sandra Friel
Mr. and Mrs. Robert Gamberg
Dr. and Mrs. Alfred E. Goldman
Eden Graber and Rick Tilton
Greater Philadelphia Chamber of Commerce
Dr. Jennifer Gross and Mr. Eli Gross
Mr. and Mrs. Patrick E. Hanraty
John G. Harkins, Jr.
Dr. and Mrs. Scott H. Herbert
Mr. L. Harvey Hewitt
Hillel of Greater Philadelphia
The Honorable and Mrs. Harris N. Hollin
Holt Logistics Corp.
Howson & Howson LLP
Carol and Lawrence Huff
Ms. Kelly Irwin
Mr. and Mrs. Stephen J. Izzi
Mr. and Mrs. Stephen R. Jacobs
Ms. Janet Kardon
Mr. and Mrs. James P. Kimmel, Jr.
Mr. and Mrs. William Kirchhoff
Mr. and Mrs. Leonard M. Klehr
Mr. Zachary Klehr
Mr. and Mrs. Harvey S. Kronfeld
Polly and Bob Lam
Ms. Elaine Levitt
Mr. and Mrs. Robert P. Levy
Mr. James C. Li and Mrs. Audrey Yeung
Mr. and Mrs. James J. Lynch
Mr. and Mrs. Larry Magid
Mr. Drew Moss
Maureen Murphy, Ph.D.
Mr. and Mrs. Charles Murray
Mr. and Mrs. Ronald J. Naples
Mr. and Mrs. Henry N. Nassau
Dr. and Mrs. Paul Allan Offit
Mr. and Mrs. Dean C. Pappas
Penn Center for AIDS Research
Dr. Richard Pestell
Mr. Edward A. Piscopo
Pottsville Broadcasting Co., Inc.
Vincent E. Price, Ph.D.
Alan and Louise Reed
Mrs. Claire Reichlin
Mr. and Mrs. Stanley Reichlin
Mr. William J. Reulbach and Ms. Lisa Bierly
Dr. and Mrs. Donald Vail Rhoads
Mr. Samuel Vail Rhoads
Mr. Jay Rosenbluth
Dr. Harry Rosenthal in Memory of the
Rosenthal-Moellerich-Voehl Families
Mr. and Mrs. Marvin J. Rounick
Mr. and Mrs. Edward J. Ryan
Saul Ewing LLP
Karen and George Sauter
Mr. James R. Schaeffer and Ms. Nicole Dresnin
Mr. and Mrs. Richard Seitchik
Franz W. Sichel Foundation
Mr. and Mrs. Howard A. Silverman
Mr. and Mrs. Morton H. Simkins
Mr. and Mrs. Edward Tawil
Tim Turnham Ph.D.
University City Science Center
University of the Sciences in Philadelphia
David U’Prichard Ph.D.
Mr. and Mrs. Charles H. Vetterlein
Donna and Lester Weinraub
Mr. and Mrs. Raymond H. Welsh
Wilf Family Foundations
Miss Caroline P. Wistar
Mr. Gil Wistar
Mr. James B. Wistar
The Worsham Family Foundation
BENEFACTORS $500+
Mrs. Donna Aird
Mr. and Mrs. Robert M. Alper
Mr. Thomas J. Baldoni
Mr. Peter A. Benoliel and Ms. Willo Carey
Luther Weldon Brady, M.D.
Dr. Margo Ann Brinton
Mr. Carl Buchholz
Mr. and Mrs. Cummins Catherwood, Jr.
Mr. and Mrs. Robert Hacker Clapham, Sr.
Mr. Michael Connelly
Mr. and Mrs. Samuel E. Dennis
Dr. and Mrs. John DiIulio
Mr. and Mrs. Howard Fischer
Mr. John W. Fowler, Jr.
Mr. and Mrs. Andrew A. Goldman
Mrs. Barbara Gomes
Mr. and Mrs. Robert Goodman
Gospel Temple Baptist Church
Dr. and Mrs. Allan Greenspan
Mr. Joshua S. Gross
Mr. Lawrence Hollin
Dr. F. Kay Huebner
Barbara B. Knowles, Ph.D.
Dr. and Mrs. David Koch
Mr. and Mrs. Brent Kornman
Mrs. Lillian S. Kosloff
Mr. and Mrs. Mark Lenet
Mr. Edward W. Levin
Mrs. Judith Lieb
Mr. and Mrs. Sheldon J. Liss
Alexa Lustig
Maureen and James McCabe
Mrs. Joan Miller
Mr. and Mrs. Robert A. Miller
Leah Reinhard
Dr. and Mrs. Kenneth Scott Resnik
Mr. and Mrs. Richard M. Rosenbleeth
Dr. Caroline S. Rhoads
Nancy H. Rhoads and Adam L. Glick
Lucy B. Rorke-Adams, M.D.
Dr. and Mrs. Louis F. Rose
Mr. and Mrs. Louis E. Rousso
Mr. Michael Roynan
Siegelvision
Mr. and Mrs. Charles H. Silverman
Ms. Cathi Snyder
Mr. William Stamps
Ellen R. Stubbs, M.D.
T & N Van Services
Monica and Thomas Teesdale
Dr. Lynne Tobin
Mr. and Mrs. Gilbert Tucker
Mrs. Kevin Tucker
Mr. Joseph Trainor
Mr. David Urbach
WHYY, Inc.
Dr. and Mrs. Michael Widlitz
Mr. and Mrs. Bernard Zolot
* deceased
Each of our donors is important to us and we make every effort to follow the donor’s preferences when compiling the annual report list. Gifts
mentioned exclude in-kind donations and multiple-year pledges. Please notify us of any omissions or errors so we can correct our records.
Please contact the development office at 215.898.3930 or email development@wistar.org.
THE PEW
CHARITABLE
TRUSTS
UNPARALLELED CONTRIBUTIONS
The Pew Charitable Trusts has been a
longtime supporter of The Wistar Institute.
Since 1969, Pew has generously awarded 27
grants, totaling more than $12 million. Pew
awards have supported a variety of purposes
including building renovations, specialized
equipment purchases and focused research
assistance. Since 1992, support from Pew
has enabled Wistar to recruit 23 researchers
and to continue enlisting upper echelon
scientific investigators conducting worldclass cancer research.
In addition, several Wistar scientists have
been awarded individual grants through
the Pew Scholars Program in the Biomedical
Sciences. Every year, early-career researchers
from across the nation compete for 22
awards, each providing a total of $240,000
in funding over four years, to develop their
scientific projects.
The Pew Charitable Trusts is a nonprofit
organization that applies a rigorous,
analytical approach to improve public policy,
inform the public, and invigorate civic life.
In Philadelphia, Pew encourages a thriving
arts and cultural community; supports the
health and welfare of the region’s most
vulnerable populations; informs discussion
on important issues facing the city; and,
more broadly, strengthens the area’s appeal
to residents and visitors alike.
Previously supported Wistar
scientists: Maureen Murphy,
Ph.D., Rugang Zhang, Ph.D.,
and Dmitry Gabrilovich,
M.D., Ph.D.
HERITAGE SOCIETY
The Wistar Heritage Society recognizes the foresight
and generosity of individuals who elect to perpetuate
their support of biomedical research by including
the Institute in their wills or estate plans. The Wistar
Institute appreciatively recognizes these members as
of December 31, 2014:
Francis X. Bresnan
Ira Brind
June H. Chern
Peter E. Corrado
Harold M. Davis
Joan M. Farkas
Dr. and Mrs. Jerome I. Flicker
Robert A. Fox
Bruce A. Gillespie
Stan and Arlene Ginsburg Family Foundation
Dr. and Mrs. Alfred E. Goldman
Mr. and Mrs. Bruce A. Goodman
Joseph F. Grusemeyer
Dorothee M. Herlyn, D.V.M., D. Sc.
Meenhard Herlyn, D.V.M., D. Sc.
The Honorable Harris N. Hollin
Mrs. Constance Jordan
Miss Rivka Kaestner
Russel E. Kaufman, M.D.
Herbert Kean, M.D.
Ms. Deborah Komins
Evelyn S. Kritchevsky
Mr.* and Mrs. Thomas F. Lafferty
Howard L. Lipschutz
Glorita P. Maida
Kurtis L. Meyer
Paula R. Meyer
E. K. Pomerantz Miller
Sandya Narayanswami, Ph.D.
Ms. Carol B. O’Neill
Ms. Rosetta Perno
Elizabeth A. Pesce and Timothey P. Pesce
Seymour S. Preston III and Jean E.H. Preston
Lt. Col. Carolyn Reinbold
Dr. Harry Rosenthal in Memory of the RosenthalMoellerich-Voehl Families
Emily Brown Shields
Ed Sickles Family
James B. Wistar
Joan H. Wister
The Wistar Postdoctoral Program
supports the next generation of Wistar
scientists with programs tailored to
enhance their training. At any one time,
there are between 75-100 postdoctoral
fellows and 45 graduate students at The
Wistar Institute, and outside the rigors
of work, postdocs make time for fun.
On Aug. 8, 2014, the Annual Ice Cream
Social took place. A 50:50 raffle raised
funds for educational programs and
attendees hung around until each and
every last scoop of gelato was finished.
WISTAR FAMILY GIFTS
The Wistar Institute was founded in 1892 through
generous gifts from Isaac Jones Wistar, a prominent
Philadelphia lawyer and former Civil War Brigadier
General, in honor of his great uncle, Caspar Wistar,
M.D., a physician and the author of the first American
textbook on anatomy. Isaac Wistar’s descendants, as
well as those of Dr. Caspar Wistar, continue to support
the Institute to this day. The Wistar Institute gratefully
acknowledges the following family members who
made contributions in 2014.
Ms. Mary Rhoads Alexander
Marion and Frederic Ballard
Charles J. Bauernschmidt, Esquire
Mrs. Laura J. Belman
Mr. Nicholas W. Brown
Sandra and Robert Clapham
Mrs. Barbara Lea Couphos
Mrs. Eleanor M. Cox
Beth and J. Brooke Gardiner
Marin Shawn Haynes
Ms. Elizabeth Wistar Little
Mr. William M. MacDonald
Mrs. Pierre E. Martin
Martha and I. Wistar Morris III
Mrs. Elizabeth Haines Morris
Anne Rhoads and Noureddine Melikechi
Dr. Caroline S. Rhoads
Dr. and Mrs. Donald Vail Rhoads
Nancy H. Rhoads and Adam L. Glick
Mr. Samuel Vail Rhoads
Inés and William Rhoads
Gloria Marin Darthea Sharples, Ph.D.
Mr. C. Cresson Wistar
Mr. and Mrs. Caleb C. Wistar IV
Miss Caroline P. Wistar
Mr. Gil Wistar
Mr. James B. Wistar
Brigadier General Isaac Jones Wistar’s sword ushered
in a new era of Wistar Science at the opening
ceremony of the Robert and Penny Fox Tower on
Sept. 12, 2014. Surrounded by Rhoads family
members and James Wistar, Dr. Russel Kaufman cut
the ribbon for the official opening of the Robert and
Penny Fox Tower before a crowd of hundreds.
THE WISTAR INSTITUTE
BOARD OF TRUSTEES
OFFICERS
CHAIR
Helen P. Pudlin, Esq.
Retired Executive Vice President
and General Counsel
The PNC Financial Services Group, Inc.
VICE CHAIR
Richard M. Horowitz
President
R.A.F. Industries, Inc.
SECRETARY
Maida Milone
Vice President of Strategic Planning
and Business Development, Devereux
Ira Brind
President
Brind Investments, Inc.
Ronald L. Caplan
President
Philadelphia Management Corp.
Brian H. Dovey
General Partner
Domain Associates
Daniel K. Fitzpatrick, C.F.A.
President and CEO
Citizens Bank of PA/NJ/DE/NY
Robert A. Fox
Chairman and CEO
R.A.F. Industries, Inc.
TREASURER
Alan Stiles
Chief Operating Officer
The Wistar Institute
L. Patrick Gage, Ph.D.
Founder & President
enGage Biotech Consulting
MEMBERS
Mark L. Greenberg, Ph.D.
Provost
Senior Vice President for
Academic Affairs
Drexel University
Elizabeth McKee Anderson Worldwide Vice President
Vaccines, Global Strategic Marketing
Johnson & Johnson
Van Billet
Robert S. Blank
Partner
Whitcom Partners
Douglas S. Briggs
Joseph A. Goldblum
President
G-II Equity Investors, Inc.
Herbert Kean, M.D.
Samuel V. Rhoads
Executive Vice President
Philadelphia Industrial
Development Corporation
Robert H. Rock
President
MLR Holdings, LLC
Gerald B. Rorer
Adele K. Schaeffer
Paul J. Schmitt
Managing Director
Novitas Capital
Milton S. (Tony) Schneider
Principal & Founder
The Glenville Group, Inc.
William A. Slaughter, Esq.
Partner
Ballard Spahr LLP
Judith E. Soltz, Esq.
David V. Wachs
Daniel H. Wheeler
President
Pea Vine Properties
Edward Ziff, Ph.D.
Professor, Department of Biochemistry
NYU School of Medicine
Perry A. Lerner*
Chairman & CEO
Crown Global Insurance Group, LLC
Susan S. McDonald, Ph.D.
President & CEO
NAXION
Abraham L. Morris
Co-CEO
Sunlogics
Albert Ominsky, Esq.
Ominsky & Ominsky, P.C.
Arthur M. Pappas
Managing Partner
Pappas Ventures
Vincent Price, Ph.D.
Provost
Steven H. Chaffee Professor of
Communication, Annenberg
School for Communication
University of Pennsylvania
EMERITUS BOARD
MEMBERS
Harold M. Davis
Chairman, Realen Properties
Peter C. Dougherty, Ph.D.
Chairman, Department of Immunology,
St. Jude Children’s Research Hospital
Nobel Laureate in Physiology
or Medicine (1996)
Member, National Academy of Sciences
The Honorable Harris N. Hollin
Faye Olivieri Kozich
Seymour S. Preston, III
The Millrace Group
Doris Taxin
* = new in 2014
STAFF AND ADMINISTRATION
STAFF AND
ADMINISTRATION
Jo-Ann Mendel, M.B.A.
Director, Human Resources
Marianne O’Neill
Director, Research Financial
Administration
Russel E. Kaufman*
President and CEO
Raymond Preis
Director, Information Systems
Dario C. Altieri, M.D.*
Director, The Wistar Institute
Cancer Center
Executive Vice President
Chief Scientific Officer
Robert and Penny Fox
Distinguished Professor
Stephen Tustin, C.P.A.
Director, Finance and Controller
William H. Wunner, Ph.D.
Professor
Director, Academic Affairs
Director of Outreach Education and
Technology Training
Alan Stiles
Chief Operating Officer
Joseph Trainor
Chief Financial Officer
Andrew Peabody
Chief Information Officer
Elizabeth B. O’Brien, Esq.
Vice President, Legal and
External Affairs
Eden Graber 1
Vice President, Development
and Marketing
Heather A. Steinman, Ph.D., M.B.A.
Vice President, Business Development
Executive Director, Technology Transfer
Associate Vice President,
Faculty Affairs
Josie Burri 1
Director, Major Gifts
Greg Lester 1
Acting Director, Communications
Elyse Hoffmann
Director, Donor Relations
and Special Events
Van Cherington, Ph.D.
Director, Science Administration
April Miller
Director, Library Services
Curator of The Wistar Museum
Collections
James E. Zaleski
Director, Facilities
CANCER CENTER
ADMINISTRATION
Dario C. Altieri, M.D.
Director
Frank J. Rauscher, III, Ph.D.
Deputy Director
Paul Lieberman, Ph.D.
Program Leader, Gene
Expression and Regulation
Hilary Koprowski, M.D.,
Endowed Professor
Program Leader, Molecular
and Cellular Oncogenesis
Associate Director, Education
and Career Development
David W. Speicher, Ph.D.
Program Co-Leader, Molecular
and Cellular Oncogenesis
Caspar Wistar Professor in
Computational and Systems Biology
José Conejo-Garcia, M.D., Ph.D.
Program Leader, Tumor
Microenvironment and Metastasis
Dmitry I. Gabrilovich, M.D., Ph.D.
Program Leader, Translational
Tumor Immunology
Christopher M. Davis Professor
Luis J. Montaner, D.V.M., D.Phil.
Associate Director, Shared Resources
Herbert Kean, M.D., Family Professor
Nicholas J. Petrelli, M.D.
Associate Director, Translational
Research, Helen F. Graham Cancer
Center & Research Institute
Marianne O’Neill
Associate Director, Cancer Center
Support Grant Finances
Lisa Sideras
Associate Director, Cancer
Center Administration
Mark Drinker
General Manager, Shared
Resources Operations
CANCER CENTER
RESEARCH PROGRAMS
GENE EXPRESSION
AND REGULATION
Professors
Program Leader
Hilary Koprowski, M.D.,
Endowed Professor
Kazuko Nishikura, Ph.D.
Frank J. Rauscher, III, Ph.D.
Associate Professors
Ken-ichi Noma, Ph.D.
Emmanuel Skordalakes, Ph.D.
Rugang Zhang, Ph.D.
Senior Staff Scientists
Zhong Deng, Ph.D.
Hongzhuang Peng, Ph.D.
Staff Scientists
Troy E. Messick, Ph.D.
Masayuki Sakurai, Ph.D.
Associate Staff Scientists
Jayaraju Dheekollu, Ph.D.
Jayashree Karar, Ph.D.
Fan Lai, Ph.D.
Fang Lu, Ph.D. ¹
Osamu Iwasaki, Ph.D.
MOLECULAR AND
CELLULAR ONCOGENESIS
Professors
Program Leader
Livio Azzoni, M.D., Ph.D.
Kiranmai Gumireddy, Ph.D.
Michael P. O’Connell, Ph.D. ¹
Emmanouil Papasavvas, Ph.D.
Costin Tomescu, Ph.D.
Program Co-Leader
Caspar Wistar Professor in Systems
and Computational Biology
Staff Scientists
Adina-Monica Vultur, Ph.D.
Amaya Wolf, Ph.D. ¹
Ellen Heber-Katz, Ph.D. ¹
Louise C. Showe, Ph.D.
Melanie R. Rutkowski, Ph.D.
Tom L. Stephen, Ph.D.
Thomas C. Condamine, Ph.D.
Batool Shannan, Ph.D.
Haikun Wang, Ph.D. ¹
Qin Liu, M.D., Ph.D.
Harold Riethman, Ph.D.
TRANSLATIONAL TUMOR
IMMUNOLOGY
Assistant Professors
Susan Janicki, Ph.D.
Jessie Villanueva, Ph.D.
Professors
Dmitry I. Gabrilovich, M.D., Ph.D.
Program Leader
Christopher M. Davis Professor
Meenhard Herlyn, D.V.M., D.Sc.
Caspar Wistar Professor in
Melanoma Research
Michael K. Showe, Ph.D. ¹
Tao Wang, Ph.D. ¹
Staff Scientists
Noor B. Dawany, Ph.D. ¹
Jagadish C. Ghosh, Ph.D.
Sharmistha Pal, Ph.D. ¹
Young Chan Chae, Ph.D.
Michele Tavecchio, Ph.D.
TUMOR
MICROENVIRONMENT
AND METASTASIS
Professors
Dario C. Altieri, M.D.
José Conejo-Garcia, M.D., Ph.D.
Program Leader
Hui Hu, Ph.D. ¹
Qihong Huang, M.D., Ph.D.
Yulia Nefedova, M.D., Ph.D.
Ashani Weeraratna, Ph.D.
Research Assistant Professors
Mizuho Kalabis, M.D., Ph.D.
Clemens Krepler, Ph.D.
Rajasekharan Somasundaram, Ph.D.
Andrew Caton, Ph.D.
Jan Erikson, Ph.D.
Luis J. Montaner, D.V.M., D.Phil.
Herbert Kean, M.D., Family Professor
Associate Professor
Chih-Chi Hu, Ph.D.
Assistant Professor
Scott E. Hensley, Ph.D.
CANCER CENTER
SHARED RESOURCES
Shared Resources
Scientific Directors
Andrew Caton, Ph.D.
Luis J. Montaner, D.V.M., D. Phil.
Shared Resources
Managing Directors
Livio Azzoni, M.D., Ph.D.
Celia Chang, Ph.D.
Denise DiFrancesco, A.S.,
R.L.A.T., I.L.A.M., C.M.A.R.
Jeffrey S. Faust, B.S., M.B.A.
James Hayden, B.A., R.B.P., F.B.C.A.
Robert Hills, Ph.D.
Andrei Kossenkov, Ph.D.
David Schultz, Ph.D. ¹
Hsin-Yao Tang, Ph.D.
Dr. Meenhard Herlyn’s lab
pioneered the use of threedimensional “artificial skin” to
study melanoma cells and how
they interact amid normal cells.
The ability to create artificial skin
gives Herlyn’s lab unique insight
into understanding the way
melanoma cells work, and also
serves as a proving ground for
future therapeutics.
VACCINE CENTER
Hildegund C.J. Ertl, M.D.
Director, Caspar Wistar Professor
in Vaccine Research
Assistant Professor
Scott E. Hensley, Ph.D.
Zhi Quan Xiang, M.D.
Xiang Yang Zhou, M.D., Ph.D.
MELANOMA
RESEARCH CENTER
Meenhard Herlyn, D.V.M., D.Sc.
Director
Members
Russel E. Kaufman, M.D.
Jessie Villanueva, Ph.D.
Ashani Weeraratna, Ph.D.
CENTER FOR SYSTEMS
AND COMPUTATIONAL
BIOLOGY
Director
Associate Director and
Director of Genomics
ALBERT R. TAXIN BRAIN
TUMOR RESEARCH CENTER
ROBERT A. FOX
STRUCTURAL
BIOLOGY CENTER
Member
Emmanuel Skordalakes, Ph.D.
Director
George G. Prendergast, Ph.D. 4
Lankenau Institute for Medical Research
Ulrich Rodeck, M.D.
Thomas Jefferson University
Charles E. Rupprecht, V.M.D., Ph.D.
Global Alliance for Rabies Control
Thomas D. Stamato, Ph.D. 4
Lankenau Institute for Medical Research
PROFESSORS EMERITI
Clayton Buck, Ph.D.
Roger M. Burnett, Ph.D.
Walter Gerhard, M.D.
Dorothee Herlyn, D.V.M., D.Sc.
Elliot Levine, Ph.D.
Stanley A. Plotkin, M.D.
Robert Roosa, Ph.D.
Leonard Warren, M.D., Ph.D.
Zofia Wroblewska, M.D.
ADJUNCT AND
AFFILIATE FACULTY
Adjunct Professors
Stephen M. Albelda, M.D. 4
Adjunct and Affiliate
Michael R. Betts, Ph.D. 4
Horace M. Delisser, M.D. 4
K. Ann Jeglum, V.M.D.
Veterinary Oncology Services
and Research Center
Steven B. McMahon, Ph.D.
Thomas Jefferson University
Zhi Wei, Ph.D. 4
New Jersey Institute of Technology
Xiaowei Xu, M.D., Ph.D. 4
Richard Assoian, Ph.D. 4
Adjunct and Affiliate
Ravi Amaravadi, M.D. 4
Shelley Berger, Ph.D.
Devraj Basu, M.D., Ph.D. 4
Gerd Blobel, M.D., Ph.D. 4
Children’s Hospital of Philadelphia
David Garlick, Ph.D. 4
Histo-Scientific Research Laboratories
Timothy Block, Ph.D.
Drexel University
F. Bradley Johnson, M.D., Ph.D. 4
Anthony Capobianco, Ph.D.
University of Miami
Alexander Roesch, M.D.
The Saarland University Hospital
Dennis E. Discher, Ph.D. 4
Fiona Simpkins, M.D.
Cesare Furlanello, Ph.D.
Fondazione Bruno Kessler
Julia C. Tchou, M.D., Ph.D. 4
Phyllis A. Gimotty, Ph.D. 4
Mark I. Greene, M.D., Ph.D., F.R.C.P. 4
Thanos D. Halazonetis, D.D.S., Ph.D. 4
University of Geneva
CENTER FOR CHEMICAL
BIOLOGY AND
TRANSLATIONAL MEDICINE
Nicholas J. Petrelli, M.D. 4
Helen F. Graham Cancer Center
& Research Institute
Katherine A. High, M.D.
Children’s Hospital of Philadelphia
Ronen Marmorstein, Ph.D. 4
Reynold A. Pannettieri, Jr., M.D. 4
LEGEND
1
Departed in 2014
2
Secondary appointment
3
Deceased 2014
4
Affiliate member of the Cancer Center
*
On March 2, 2015, Russel E. Kaufman,
M.D., stepped down as president and CEO
to become president emeritus of The Wistar
Institute. Dario C. Altieri, M.D., succeeded
Kaufman as president and CEO of The
Wistar Institute and will continue to serve as
director of Wistar’s Cancer Center.
FINANCIALS
TOTAL NUMBER
OF EMPLOYEES
NUMBER OF COUNTRIES*
OF ORIGIN REPRESENTED
NUMBER OF
LABORATORIES
NUMBER OF
POST-DOCTORAL FELLOWS
NUMBER OF
PRE-DOCTORAL FELLOWS
NUMBER OF
VISITING SCIENTISTS
359 31 31
45 33 10
*Albania, Argentina, Austria, Brazil, Bulgaria, Canada, China, Ecuador, France, Germany, Greece, Hungary, India, Indonesia, Italy,
Jordan, Japan, Korea, Luxembourg, Peru, Poland, Russia, Singapore, Spain, Sri Lanka, Syria, Taiwan, United Arab Emirates, United
Kingdom, United States, Vietnam
PATENTS ISSUED
SHARED RESOURCES
U.S. Patent No. 8,669,243
Steroid-Derived Cyclopamine
Analogs and Methods for
Using the Same in the Prevention
or Treatment of Cancer
Filed: 06/15/2011
Issued: 03/11/2014
Inventors: Nadia Dahmane
Jeffrey D. Winkler
Animal Facility
Bioinformatics Facility
BSL-3 Facility
Flow Cytometry Facility
Genomics Facility
Histotechnology Facility
Imaging Facility
Molecular Screening Facility
Phlebotomy Facility
Protein Expression Facility
Proteomics Facility
Research Supply Center
Translational Research
Management Facility
Vector Core
U.S. Patent No. 8,759,367
Compounds and Methods
for the Prevention and
Treatment of Cancer
Filed: 10/04/2011
Issued: 06/24/2014
Inventors: Nadia Dahmane
Jeffrey D. Winkler
Andre Isaacs
SOURCES OF FUNDS
● Federal grant funding
$ 32,439,000
51%
● Foundation and other private funding
4,773,000
8%
● State funding
606,000
1%
● Corporate-sponsored research
1,401,000
2%
● Unrestricted contributions
558,000
1%
● Capital campaign contributions
3,125,000
5%
● Technology transfer 18,209,000
28%
● Investment and other 2,849,000
4%
$63,960,000
100%
SOURCES
OF FUNDS
FINANCIALS
USES OF FUNDS
● Direct research
$ 32,565,000
52%
● General and administrative 11,055,000
17%
● Operation and maintenance of plant
7,655,000
12%
● Depreciation/disposals of capital assets
5,550,000
9%
● Interest expense
898,000
1%
● Pension and interest rate swap losses
5,527,000
9%
$ 63,250,000100%
Change in net assets $
710,000
USES
OF FUNDS
LEADERSHIP COUNCIL
Zachary Klehr
Executive Vice President, Franklin
Square Capital Partners
Paul N. Urick, R.Ph.
Senior Vice President of Pharmaceutical
Operations, Cigna Corporation
CO-CHAIRS
James C. Li
Vice President, Commercial Lending,
First Federal of Bucks County
Dr. Aubrey Watkins III
Director, Business Development
& Licensing (Transactions
Manager), Merck
Max Berger
President, MBA Equities
Donna F. Weinraub, CPCU, ARM
Senior Vice President, Corporate Risk
Solutions, Willis of Pennsylvania
Michelle Mayer
Account Manager, Managed
Healthcare Services, Lilly USA
Bryan Weingarten
Chief Executive Officer, WP Realty
MEMBERS
Kevin P. McDermott, CFP®, RFC
Founding Partner, The
Philadelphia Group
Jeremiah J. White, Jr.
President and CEO, Jeremiah
J. White & Associates
Mary E. Bak
Partner, Howson & Howson LLP
Jennifer Mendel
Principal Partner, Blue Fox Advisors LLC
Marla Conley, Esq.
Nonprofit Organizations Practice Group
Co-Chair, Schnader Attorneys at Law
Patrick M. Oates, Ph.D.
Vice President, Science Education,
Universal Companies
James Wistar
Chairman, President and CEO,
Everite Door Company
Kenneth J. Davis, Esq.
Partner, Morgan Lewis
Elizabeth A. Pesce
CFO, Beco Kitchens and Bathrooms
Elizabeth Gabor
Real Estate Manager, IKEA Group
Edward Piscopo
Regional Director of Economic
Development, PECO, an
Exelon Company
Keith Gaspard
Partner - Life Sciences,
Odgers Berndtson
Bruce A. Gillespie
Retired Commercial Banker
Merle Gilmore
Founder and Principal, Merle
Gilmore & Associates
Joseph F. Grusemeyer
Scott H. Herbert, M.D.
Chief, Radiation Oncology,
The Rosenfeld Cancer Center,
Abington Memorial Hospital
Liza Herzog
Director of Research,
Philadelphia Education Fund
Larry Hollin
Partner, Arch Street Advisors
Rick Horowitz
President, RAF Industries, Inc.
Carol G. Huff
President, Real Estate
Investment Strategies, Inc.
Sharon Tobin Kestenbaum
President, Bala Properties Group, Inc.
Ellen Riccobene, M.D.
Medical Director,
Independence Blue Cross
Craig F. Zappetti
Partner, Saul Ewing LLP
THE AMBASSADORS OF
Lynsie Solomon (chair)
Eric Rugart
Co-Founder, ZSX Medical
Katie Adams
Edward J. Ryan
Executive Advisory Board,
Wells Fargo Bank
Ian Michael Crumm
Jim Schaeffer
President and Founder,
Ruby’s of Pennsylvania
Ken Greenberg
Evan Solomon
CEO, EFS Networks Inc.
Lynsie Solomon
Department of Public Property,
City of Philadelphia
Alex Stanbach
Project Manager, UBC: An
Express Scripts Company
Allison Becker
Peter Dilsheimer
Gabriela Guaracao
Elizabeth Lampen Kim
Marc Kim, M.D.
Alexa Lustig
Michael Magnatta
Julia Sherwood Murphy
Katie Pellecchia
Jenny Perkins
Greg Stanbach
Senior Vice President, RBS Citizens
Leah Reinhard
James D. Troyer, CFA
Principal and Portfolio Manager,
The Vanguard Group
Garrett Getlin Snider
Cory Siegfried
3601 SPRUCE STREET
PHILADELPHIA, PA 19104-4265
215.898.3700
The Wistar Institute’s 2014
Annual Report was produced by the
Office of Development and Marketing
ELYSE HOFFMANN
Director of Donor Relations and Special Events
DARIEN SUTTON
Senior Media Relations Associate
BEN LEACH
Digital Content Specialist
JESSICA MARTINEZ
Administrative Coordinator, Development and Marketing
WRITERS: Darien Sutton, Ben Leach, Laura Feragen,
Allyson Groff
DESIGN: Anne Marie Kane, Imogen Design
COVER DESIGN: Cindy Jensen Graphic Design
PHOTOGRAPHY: Daniel Burke Photography,
Tommy Leonardi, Darien Sutton
The Wistar Institute is an equal opportunity/affirmative
action employer. It is the policy of The Wistar Institute to
provide equal employment opportunities to all individuals
regardless of race, color, creed, religion, national origin,
ancestry, sex, age, veteran status, disability, sexual
orientation, gender identity, or on the basis of genetic
information, or any other characteristic protected by
federal, state, or local law, with respect to all terms and
conditions of employment.

2014 Annual Report - The Wistar Institute

Transcription

Similar documents

"HEY, THAT TICKLES"—Eleven-month

File

Mrs. Starr`s Second Grade Class loves going to the computer lab

May 18, 2012 - Urbana City Schools

Funeral Services For Mrs. Jennie Thompson are rteld

BOSSLey Biz - Bossley Park High School

mrs. flutterbee`s music and movement assemblies

Dear New Friend, I am so excited to hear that you are in my class

Welcome to Year 9 2015

2010 Part 2

PARTNERS IN DISCOVERY - The Wistar Institute